| Autor: |
Adachi T; Safety Research Laboratory, Tanabe Seiyaku Co., Ltd., 3-16-89 Kashima, Yodogawa-ku, Osaka 532-8505, Japan., Kuwamura Y, Fujiwara T, Tanimoto N, Nishimura T, Koguchi A, Kobayashi K, Sasaki Y, Yamaguchi C, Honda T, Kawashima K, Yuasa H, Yamamura T, Inui T |
| Jazyk: |
angličtina |
| Zdroj: |
The Journal of toxicological sciences [J Toxicol Sci] 2002 Aug; Vol. 27 (3), pp. 147-63. |
| DOI: |
10.2131/jts.27.147 |
| Abstrakt: |
As a part of the ILSI-HESI Alternative to Carcinogenicity Testing (ACT) program, we performed a 26-week carcinogenetic study of nonmutagenic drug, ampicillin (ABPC) in Tg-rasH2 mice. ABPC was given to Tg-rasH2 mice (0, 350, 1000, 3000 mg/kg, p.o.) and Non-Tg mice (0, 3000 mg/kg, p.o.) daily for 26 weeks. As a positive control, a single dose of MNU was administered once to Tg-rasH2 mice (75 mg/kg, i.p.). In this study, Tg-rasH2 mice did not demonstrate any increases in tumor development in response to ABPC. Thus, ABPC had no carcinogenicity in the 26-week carcinogenesis study in Tg-rasH2 mice or in a 2-year carcinogenesis study in B6C3F1 mice. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
